Regal Assets Analytics

Karyopharm’s Cancer Drug Achieves Impressive Results

By |2020-03-11T15:33:41-04:00December 2nd, 2018|Tags: , , , , , |

Karyopharm Therapeutics Inc. (NASDAQ:KPTI) reported impressive results on December 1, 2018 for its lymphoma drug candidate Selinexor, noting patients who experienced [...]

SanaCurrents BioTech Research Service Inaugural Reports on EIDX and GLMD

By |2020-03-11T15:33:54-04:00November 18th, 2018|Tags: , , , , , , |

Last week, Galmed Pharmaceuticals  (NASDAQ:GLMD) shares climbed as high as $9.90 per share this week, up approximately 7% on the [...]

Update on Eidos Therapeutics after Positive Phase II Results

By |2018-12-04T11:25:37-05:00November 12th, 2018|Tags: , , , , |

Eidos Therapeutics, Inc. (NASDAQ:EIDX) shares are up as much as 17% today after the company reported positive phase II results [...]

Galmed (GLMD) – November Catalyst: Aramchol

By |2019-01-22T10:04:09-05:00November 6th, 2018|Tags: , , , , |

November Catalyst: Aramchol SanaCurrents forecasts an advantageous probability Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) will post positive results in an abstract report focused on [...]

Eidos Therapeutics (EIDX) – 4Q Catalyst: AG10 phase II data

By |2019-01-22T10:04:18-05:00November 6th, 2018|Tags: , , , |

4Q Catalyst: AG10 phase II data Based on its analytics score, SanaCurrents gives a superior sentiment rating that Eidos Therapeutics, [...]

SanaCurrents Introduction – Turn to the Biotech Experts to Maximize Your Returns

By |2019-05-03T11:54:55-04:00November 4th, 2018|Tags: , , , , , , |

Introducing SanaCurrents Introducing SanaCurrents, a research service for the serious and sophisticated biotech investor. Founder of SanaCurrents, Bill Langbein, finally [...]

Go to Top